Handelsbanken Fonder’s Sage Therapeutics SAGE Stock Holding History

Handelsbanken Fonder’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,844	Closed	-$259K	–	1581
2024 Q1	$259K	Buy	13,844 +1,200	+9%	+$27.7K	﹤0.01%	1433
2023 Q4	$274K	Buy	12,644 +2,900	+30%	+$57.5K	﹤0.01%	1413
2023 Q3	$201K	Hold	9,744	–	–	﹤0.01%	1467
2023 Q2	$458K	Hold	9,744	–	–	﹤0.01%	1110
2023 Q1	$409K	Hold	9,744	–	–	﹤0.01%	1102
2022 Q4	$372K	Hold	9,744	–	–	﹤0.01%	1127
2022 Q3	$382K	Hold	9,744	–	–	﹤0.01%	1107
2022 Q2	$315K	Hold	9,744	–	–	﹤0.01%	1302
2022 Q1	$323K	Hold	9,744	–	–	﹤0.01%	1480
2021 Q4	$415K	Hold	9,744	–	–	﹤0.01%	1472
2021 Q3	$432K	Hold	9,744	–	–	﹤0.01%	1439
2021 Q2	$554K	Sell	9,744 -200	-2%	-$14.1K	﹤0.01%	1304
2021 Q1	$744K	Hold	9,944	–	–	﹤0.01%	991
2020 Q4	$860K	Buy	9,944 +1,800	+22%	+$133K	0.01%	892
2020 Q3	$498K	Hold	8,144	–	–	﹤0.01%	992
2020 Q2	$339K	Buy	+8,144	New	+$296K	﹤0.01%	1157
2017 Q3	–	Sell	-14,000	Closed	-$1.11M	–	205
2017 Q2	$1.11M	Sell	14,000 -4,000	-22%	-$289K	0.03%	158
2017 Q1	$1.28M	Buy	+18,000	New	+$1.05M	0.04%	156

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Handelsbanken Fonder's SAGE Position: Q2 2024 in Review

Handelsbanken Fonder sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 13,844 shares — an estimated $259K sold.

Handelsbanken Fonder first reported a position in SAGE in Q1 2017 and held it in 18 quarters. The position peaked at $1.28M in Q1 2017. 194 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

Handelsbanken Fonder reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
Handelsbanken Fonder sold 13,844 Sage Therapeutics shares in Q2 2024, an estimated $259K.
Handelsbanken Fonder first reported a position in Sage Therapeutics in Q1 2017 and held it in 18 quarters.
Handelsbanken Fonder's Sage Therapeutics position peaked at $1.28M in Q1 2017.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on Handelsbanken Fonder's 13F filing for Q2 2024, filed 5 Aug 2024.